DNAvaccine.com Recognizes Mologen AG

DNAvaccine.com is pleased to recognize Mologen, the German based biopharmaceutical company for their outstanding contributions to the field. Also, congratulations on the recent positive data in the phase II colorectal cancer trial.

The team at Mologen are experts in DNA immunomodulation technology. Also, their MIDGE vectors are very useful for a broad spectrum of modern, DNA-based applications.

While the field of oncology is the main focus of activities, the Mologen infectious disease program utilizes DNA vaccines. They are targeting vaccine candidates that tackle diseases with a high medical need or which offer scope for significantly improving vaccines.  A number of DNA vaccines, including the well-tolerated DNA-based cancer treatment,  are on the threshold of clinical development.

You can submit recommendations for a person, team or technology to recognize for outstanding contributions to the DNA vaccine industry to victoria@dnavaccine.com.